Bulletin of Experimental Biology and Medicine

, Volume 164, Issue 5, pp 658–660 | Cite as

Combined Action of PGRPs-Hsp70 Cytotoxic Complex with Paclitaxel Improves Outcomes of Melanoma Treatment in Mice

  • E. A. Dukhanina
  • T. I. Luk’yanova
  • A. S. Dukhanin
  • S. G. Georgieva
ONCOLOGY

We studied the effect of PGRPs-Hsp70 cytotoxic complex that is analogous to natural complex secreted by cytotoxic lymphocytes and the antitumor drug paclitaxel on the development of M3 melanoma in DBA mice. Significant inhibition of tumor growth was observed in all experimental groups by days 20 and 35 of observation; paclitaxel monotherapy was less effective than administration of PGRPs-Hsp70 cytotoxic complex and its combination with paclitaxel. Pairwise comparison of Kaplan—Meier curves showed that survival was maximum in the group receiving combined therapy with PGRPs-Hsp70 cytotoxic complex and paclitaxel in comparison with groups receiving monotherapy.

Key Words

S100A4 PGRPs-Hsp70 complex paclitaxel Taxol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dukhanina EA, Lukyanova TI, Romanova EA, Dukhanin AS, Sashchenko LP. Comparative analysis of secretion of S100A4 metastatic marker by immune and tumor cells. Bull. Exp. Biol. Med. 2008;145(1):78-80.Google Scholar
  2. 2.
    Dukhanina EA, Yashin DV, Lukjanova TI, Kabanova OD, Shatalov YuV, Sashchenko LP, Gnuchev NV, Romanova EA. Administration of the cytotoxic complex Tag7-Hsp70 to mice with transplanted tumors inhibits tumor growth. Doklady Biol. Sci. 2007;414(1):246-248.CrossRefGoogle Scholar
  3. 3.
    Atlasi Y, Noori R, Marolin I, Franken P, Brandao J, Biermann K, Collini P, Grigorian M, Lukanidin E, Ambartsumian N, Fodde R. The role of S100a4 (Mts1) in Apc- and Smad4-driven tumour onset and progression. Eur. J. Cancer. 2016;68:114-124.CrossRefPubMedGoogle Scholar
  4. 4.
    Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, Brivio S, Caslini C, Stecca T, Massani M, Bassi N, Novelli E, Spirli C, Fabris L, Strazzabosco M. Low-dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. Cancer Res. 2016;76(16):4775-4784CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Dukhanina EA, Yashin DV, Galkin AV, Sashchenko LP. Unexpected deeds of familiar proteins: Interplay of Hsp70, PGRP-S/Tag7 and S100A4/Mts1 in host vs. cancer combat. Cell Cycle. 2010;9(4):676-682.CrossRefPubMedGoogle Scholar
  6. 6.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.CrossRefPubMedGoogle Scholar
  7. 7.
    Peter I, Mezzacasa A, LeDonne P, Dummer R, Hemmi S. Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3. Melanoma Res. 2001;11(1):21-30.CrossRefPubMedGoogle Scholar
  8. 8.
    Sashchenko LP, Dukhanina EA, Yashin DV, Shatalov YV, Romanova EA, Korobko EV, Demin AV, Lukyanova TI, Kabanova OD, Khaidukov SV, Kiselev SL, Gabibov AG, Gnuchev NV, Georgiev GP. Peptidoglycan recognition protein tag7 forms a cytotoxic complex with heat shock protein 70 in solution and in lymphocytes. J. Biol. Chem. 2004;279(3):2117-2124.CrossRefPubMedGoogle Scholar
  9. 9.
    Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol. Biol. Cell. 2014;25(18):2677-2681.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • E. A. Dukhanina
    • 1
  • T. I. Luk’yanova
    • 2
  • A. S. Dukhanin
    • 3
  • S. G. Georgieva
    • 2
  1. 1.V. A. Engelhardt Institute of Molecular BiologyRussian Academy of SciencesMoscowRussia
  2. 2.M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic ChemistryRussian Academy of SciencesMoscowRussia
  3. 3.N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian FederationMoscowRussia

Personalised recommendations